This article is more than 5 years old. Information may no longer be current.
Excellent long-term outcomes found with cementless titanium-tapered femoral component for THA
Patients who underwent total hip arthroplasty with a contemporary, cementless titanium-tapered femoral component inserted with a ream-and-broach technique experienced excellent outcomes, clinical durability and osteointegration at a minimum 10-year follow-up, according to results.
Researchers clinically evaluated 88 patients who underwent 100 total hip arthroplasties (THAs) with the Summit Porocoat femoral component (DePuy). Investigators studied revision rates and patients’ WOMAC score, SF-36 score, Harris Hip score, and UCLA and Tegner activity scores. Researchers assessed for loosening, osteolysis and stress shielding with radiographic evaluation. End points for revision and radiographic evidence of femoral component loosening were included in the Kaplan-Meier survivorship analysis.
At a minimum 10-year follow-up, researchers noted 66 patients were living; 20 patients were deceased; and two patients were lost to follow-up. While four hips required reoperation, results showed no femoral components were revised for aseptic loosening. Researchers noted postoperative periprosthetic fracture was the cause for revision of one femoral component. According to radiographic evaluation, all stems had bone ingrowth without evidence of component loosening. Investigators found one case of severe stress shielding. For the end points of femoral revision for loosening or femoral radiographic loosening, researchers found 100% Kaplan-Meier survivorship at 10 years.
“This contemporary, cementless titanium-tapered femoral component inserted with ream-and-broach technique demonstrated excellent results in terms of outcomes and clinical durability as well as osteointegration on radiographs at minimum 10-year follow-up,” the researchers wrote. – by Casey Tingle
Disclosures: Carlson reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.